137 related articles for article (PubMed ID: 21843575)
1. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
An SJ; Yoon YK; Kothari S; Kothari N; Kim JA; Lee E; Kim DR; Park TH; Smith GW; Carbis R
Vaccine; 2011 Oct; 29(44):7618-23. PubMed ID: 21843575
[TBL] [Abstract][Full Text] [Related]
2. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
3. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
[TBL] [Abstract][Full Text] [Related]
4. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
Ali A; An SJ; Cui C; Haque A; Carbis R
Hum Vaccin Immunother; 2012 Feb; 8(2):189-93. PubMed ID: 22426380
[TBL] [Abstract][Full Text] [Related]
5. Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine.
An SJ; Woo JS; Chae MH; Kothari S; Carbis R
Vaccine; 2015 Mar; 33(13):1614-9. PubMed ID: 25659268
[TBL] [Abstract][Full Text] [Related]
6. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
[TBL] [Abstract][Full Text] [Related]
7. A Salmonella typhi Vi conjugate vaccine.
Koul PA
N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
[No Abstract] [Full Text] [Related]
8. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.
Thiem VD; Lin FY; Canh DG; Son NH; Anh DD; Mao ND; Chu C; Hunt SW; Robbins JB; Schneerson R; Szu SC
Clin Vaccine Immunol; 2011 May; 18(5):730-5. PubMed ID: 21411598
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.
Ali A; An SJ; Cui C; Haque A; Carbis R
Hum Vaccin Immunother; 2014; 10(6):1494-8. PubMed ID: 24603090
[TBL] [Abstract][Full Text] [Related]
10. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
11. Capillary electrophoretic analysis of meningococcal polysaccharide-diphtheria toxoid conjugate vaccines.
Lamb DH; Summa L; Lei QP
Dev Biol (Basel); 2000; 103():251-8. PubMed ID: 11214245
[TBL] [Abstract][Full Text] [Related]
12. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
[TBL] [Abstract][Full Text] [Related]
13. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.
Micoli F; Rondini S; Pisoni I; Giannelli C; Di Cioccio V; Costantino P; Saul A; Martin LB
Vaccine; 2012 Jan; 30(5):853-61. PubMed ID: 22172503
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
[TBL] [Abstract][Full Text] [Related]
15. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
[No Abstract] [Full Text] [Related]
16. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
17. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
Szu SC; Klugman KP; Hunt S
Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
[TBL] [Abstract][Full Text] [Related]
18. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
[TBL] [Abstract][Full Text] [Related]
19. Development of Vi conjugate - a new generation of typhoid vaccine.
Szu SC
Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
